Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 15, Number 1, 1994

CHARLES L. WITTE, MARLYS H. WITTE, AND ANN KERWIN
Suspended Judgement Ignorance and the Process of Learning and Discovery in Medicine 1

JANET WITTES
Introduction: From Clinical Trials to Clinical Practice—Four Papers from a Plenary Session 5

HANNA BLOOMFIELD RUBINS
From Clinical Trial to Clinical Practice: Generalizing from Participant to Patient 7

C. E. DAVIS
Generalizing from Clinical Trials 11

KENT R. BAILEY
Generalizing the Results of Randomized Clinical Trials 15

CHARLES D. COWAN AND JANET WITTES
Intercept Studies, Clinical Trials, and Cluster Experiments: To Whom Can We Extrapolate? 24

CHRISTY CHUANG-STEIN
A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials 30

BONNIE P. GILLIS, ARLENE W. CAGGIULA, FRAN L. JONES, EMIL MAURER, REBECCA M. MEEHAN, MONICA E. YAMAMOTO, AND THE MODIFICATION OF DIET IN RENAL DISEASE STUDY
Features of the Nutrient Database and Analysis System for the Modification in Renal Disease Study 44

JEANNETTE Y. LEE, ALBERT OBERMAN, GERALD F. FLETCHER, JAMES M. RACZYNSKI, BARBARA J. FLETCHER, NAVIN C. NANDA, AND BETSY E. JENSEN
Design of the Training Levels Comparison Trial 59

IAN GORDON AND RAY WATSON
Letter to the Editor A Note on Sample Size Determination of Small Probabilities 77

Volume 15, Number 2, 1994

ROBERT J. CONNOR AND PHILIP C. PROROK
Issues in Mortality Analysis of Randomized Controlled Trials of Cancer Screening 81

JOHN E. OVERALL AND SUZANNE R. DOYLE
Estimating Sample Sizes for Repeated Measurement Designs 100

T. TIMOTHY CHEN AND RICHARD M. SIMON
Extension of One-Sided Test to Multiple Treatment Trials 124

THOMAS W. O'GORMAN, ROBERT F. WOOLSON, AND MICHAEL P. JONES
A Comparison of Two Methods of Estimating a Common Risk Difference in a Stratified Analysis of a Multicenter Clinical Trial 135

WILLIAM M. VOLLMER, MOLLY L. OSBORNE, STEPHANIE HERTERT, AND SONIA BUIST
Recruiting Hard-to-Reach Subjects: Is It Worth the Effort? 154

Volume 15, Number 3, 1994

HUGO W. MOSER
Suspended Judgement Reactions to the Motion Picture "Lorenzo's Oil" 161

ALISON J. KIRBY, NOYA GALAI, AND ALVARO MUÑOZ
Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes 165

NANCY R. COOK, AND BERNARD A. ROSNER
An Optimal Rule for Screening Subjects for Clinical Trials in the Presence of Within-Person Variability 173

RICHARD J. COOK
Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals 187

ETTORE AMBROSIONI, CLAUDIO BORGHI, AND BRUNO MAGNANI, ON BEHALF OF THE SMILE STUDY INVESTIGATORS
Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions 201

ANDREW R. WILLAN
Power Function Arguments in Support of an Alternative Approach for Analyzing Management Trials 211

ELIZABETH KIMBROUGH PRADHAN, JOANNE KATZ, STEVEN C. LeCLERQ, AND KEITH P. WEST Jr.
Data Management for Large Community Trials in Nepal 220

Volume 15, Number 4, 1994

CURTIS L. MEINERT
Editorial Farewell Swan Song 235
Reviewers of Controlled Clinical Trials 238
Past Editorial Board Members 243

ROGER P. GREENBERG AND SEYMOUR FISHER
Suspended Judgment Seeing Through the Double-Masked Design: A Commentary 244

GEORGE WILLS COMSTOCK
Field Trials of Tuberculosis Vaccines: How Could We Have Done Them Better? 247

SHANDE CHEN, SENG-JAW SOONG, AND RICHARD H. WHEELER
An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives 277

MILENA J. HENZLOVA, GLENDA H. BLACKBURN, EDWIN J. BRADLEY, AND WILLIAM J. ROGERS FOR THE SOLVD CLOSE-OUT WORKING GROUP
Patient Perception of a Long-Term Clinical Trial: Experience Using a Close-out Questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial 284

DIANE H. WILLIAMS AND C. E. DAVIS
Reporting of Assignment Methods in Clinical Trials 294

THE AGIS INVESTIGATORS
The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients 299

Errata 326

Announcement 327

Queries 328

Announcement (16th Annual Meeting) 329

Volume 15, Number 5, 1994

DENISE HOWEL, AND RAJ BHOPAL
Suspended Judgment Assessing Cause and Effect from Trials: A Cautionary Note 331

WILLIAM O. WILLIFORD, WILLIAM F. KROL, STUART JON SPECHLER, AND THE VA COOPERATIVE STUDY GROUP ON GASTROESOPHAGEAL REFLUX DISEASE
Development for and the Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial 335

KEITH ABRAMS, DEBORAH ASHBY, AND DOUG ERRINGTON
Simple Bayesian Analysis in Clinical Trials: A Tutorial 349

DONALD A. BERRY, MARK C. WOLFF, AND DAVID SACK
Decision Making during a Phase III Randomized Controlled Trial 360

CESAR G. VICTORA, ANA LANGER, FERNANDO BARROS, JOSÉ BELIZAN, UBALDO FARNOT, JOSÉ VILLAR, AND THE LATIN AMERICAN NETWORK FOR PERINATAL AND REPRODUCTIVE RESEARCH (LANPER)
The Latin American Multicenter Trial on Psychosocial Support during Pregnancy: Methodology and Baseline Comparability 379

GREG A GRANDITS, PHILIP R. LIEBSON, SINDA DIANZUMBA, AND RONALD J. PRINEAS
Echocardiography in Multicenter Clinical Trials: Experience from the Treatment of Mild Hypertension Study 395

MICHAEL BORENSTEIN
The Case for Confidence Intervals in Controlled Clinical Trials 411

Announcement 429

Volume 15, Number 6, 1994

ANN LENNARSON GREER
Scientific Knowledge and Social Consensus 431

MARIA MORI BROOKS, LARRY GORKIN, ELEANOR B. SCHRON, INGELA WIKLUND, JEANNE CAMPION and ROBERT B. LEDINGHAM, for the CAST Investigators
Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II) 437

TED A. GOOLEY, PAUL J. MARTIN, LLOYD D. FISHER, and MARY PETTINGER
Simulation as a Design Tool for Phase I/II Clinical Trials: An Example from Bone Marrow Transplantation 450

PETER F. THALL and RICHARD SIMON
A Bayesian Approach to Establishing Sample Size and Monitoring Criteria for Phase II Clinical Trials 463

DELLA GIBSON, ANGELA J. HARVEY, VINCENT EVERETT, and MAHESH K.B. PARMAR, on behalf of the CHART Steering Committee
Is Double Data Entry Necessary? The CHART Trials 482

ANNY H. XIANG, HARLAND N. SATHER and STANLEY P. AZEN
Power Considerations for Testing an Interaction in a $2 \times k$ Factorial Design with a Failure Time Outcome 489

THE OSTR COLLABORATIVE GROUP
The Ottawa Stroke Trials Registry Collaborative Group and the Development of the Ottawa Stroke Trials Registry (OSTR) 503

ADÈLE GREEN, DIANA BATTISTUTTA, VERONICA HART, DAVID LESLIE, GEOFFREY MARKS, GAIL WILLIAMS, PHILIP GAFFNEY, PETER PARSONS, LAWRENCE HIRST, CHRISTINE FROST, ELIZABETH ORRELL, KATHRYN DURHAM, CAROLYN LANG, and the Nambour Prevention Study Group
The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: Design and Baseline Characteristics of Participants 512

ARGYE HILLIS
Letter to the Editor 523

Announcement 524

Volume 15 Author Index 525

Volume 15 Subject Index 527

Volume Contents